Cigna slides as Evernorth PBM faces FTC-driven insulin pricing overhaul risk
Cigna shares fell as investors repriced Evernorth pharmacy-benefit earnings power after new FTC-mandated changes tied to Express Scripts’ insulin formulary and pricing practices. The stock’s drop also tracked broader managed-care sensitivity to policy and margin headlines, with CI trading down about 3% intraday.
1. What’s moving the stock
The Cigna Group (CI) moved lower today as traders focused on regulatory and litigation overhang around its Evernorth/Express Scripts pharmacy-benefit manager. The key pressure point is implementation risk and potential profit headwinds from the FTC’s February 2026 consent order that requires Express Scripts to change how member cost-sharing is calculated (moving toward net-cost based designs) and to overhaul practices tied to insulin formulary placement—steps that can reduce spread and rebate-related economics across parts of the PBM model. (news.bloomberglaw.com)
2. Why it matters for earnings
Evernorth is central to Cigna’s consolidated earnings, and the market has been wary of PBM margin compression already flagged in prior commentary about transition investments, client renewals, and near-term pressure in the pharmacy benefit services segment. With regulatory constraints now more concrete, investors are discounting the pace and magnitude of any offsetting actions (contract repricing, mix shift to specialty, and administrative fee changes) and the likelihood that operating income in the PBM unit stays soft into 2026. (benzinga.com)
3. Additional headline drag
Separate from the FTC action, Express Scripts and parent entities (including Cigna and Evernorth) have also been named in a newly filed class action tied to PBM practices, adding another layer of uncertainty around future disclosures, legal costs, and customer/client reactions. Even if ultimate financial exposure is unclear, the combination of regulatory requirements plus litigation can act as a near-term multiple compressing catalyst for managed-care names with large PBM exposure. (blbglaw.com)
4. What to watch next
Near-term focus is on management’s next updates about (a) how quickly the FTC-mandated benefit design changes roll through employer and fully insured books, (b) client retention and renewal pricing under the new model, and (c) whether Cigna reiterates or adjusts its 2026 adjusted earnings outlook in the face of PBM operating-income pressure. Any incremental guidance on Evernorth’s profit trajectory or implementation timelines is likely to drive the next sharp move in CI. (tipranks.com)